Dr Reddy's launches osteoporosis drug in US market

It launched Raloxifene hydrochloride tablets in 60 mg

 

Dr Reddy's laboratories announced on Friday that it has launched Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista tablets in the United States market, following the approval from US Food and Drug Administration (USFDA).

Evista brand and generic of this osteoporosis drug had US sales of approximately $265 million for the most recent twelve months ending in September 2016, the company said citing the IMS Health data. Evista is a registered trademark of Eli Lilly and Company.